ArticleDiscover oncology2026
Exosomal 3'tiRNA-PheGAA and interleukin-6 as novel biomarkers for non-invasive detection of NSCLC.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide. However, the diagnostic sensitivity and specificity of commonly used tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin-19 fragment (CYFRA21-1), remain limited. This study aimed to evaluate the diagnostic value of serum exosomal 3'tiRNA-PheGAA and interleukin-6 (IL-6), alone and in combination with conventional tumor markers, for the detection of NSCLC.
methodsPeripheral blood samples were collected from 110 patients with NSCLC and healthy controls. Serum exosomes were isolated, and the expression of 3'tiRNA-PheGAA was measured using quantitative real-time polymerase chain reaction (qRT-PCR). Serum levels of CEA, CYFRA21-1, and IL-6 were determined by electrochemiluminescence immunoassay (ECLIA). The diagnostic performance of individual and combined biomarkers was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsSerum levels of 3'tiRNA-PheGAA, IL-6, CEA, and CYFRA21-1 were significantly higher in NSCLC patients than in healthy controls (P < 0.0001). ROC analysis showed that the area under the curve (AUC) values for 3'tiRNA-PheGAA and IL-6 were 0.680 and 0.898, respectively. The combination of 3'tiRNA-PheGAA and IL-6 increased the AUC to 0.926, while the four-marker panel (3'tiRNA-PheGAA, IL-6, CEA, and CYFRA21-1) achieved the highest diagnostic performance with an AUC of 0.971.
conclusionsSerum exosomal 3'tiRNA-PheGAA and IL-6 may serve as promising non-invasive biomarkers for NSCLC diagnosis, and their combination with conventional tumor markers significantly improves diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.